K Number
K190540
Device Name
Ponto 4
Manufacturer
Date Cleared
2019-05-02

(59 days)

Product Code
Regulation Number
874.3302
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

Ponto 4 sound processors are intended for the following patients and indications:

· Patient with conductive or mixed hearing losses, who can still benefit from amplification of the sound. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear should be better than or equal to 45 dB HL for use with the Ponto 4 sound processor.

· Bilateral fitting is applicable for most patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2 and 4 kHz, or less than 15 dB at individual frequencies.

· Patients who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. single sided deafness or "SSD"). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz).

· Also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

The placement of a bone anchored implant is contraindicated for patient below the age of 5.

The Ponto 4 sound processors are intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS) (refer to the Ponto 4 labeling for specific compatible Cochlear models). In addition, selected Cochlear Baha sound processors can be used with the Ponto implant abutment system (refer to the Ponto labeling for compatible Baha sound processor models).

Device Description

A bone anchored hearing system consists of a sound processor connected to an implant with a skin penetrating abutment. The implant is surgically anchored in the skull bone behind the ear. Vibrations generated by the sound processor are transmitted via the implant directly through the skull bone to the cochlea as bone conduction sound processor has a coupling so that it can be easily connected to and disconnected from the abutment by the user. Alternatively, it can be connected to head band accessories, to function as a conventional bone conductor. Using a computer based fitting system the sound processor can be adjusted to the patient's individual hearing requirements. The Ponto family is intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS).

AI/ML Overview

Here's a breakdown of the acceptance criteria and study information for the Ponto 4 sound processor, based on the provided FDA 510(k) summary:

Acceptance Criteria and Device Performance

The provided document describes the Ponto 4 as a modification of a previously cleared device (Ponto 3) and relies on demonstrating similar safety and effectiveness. Therefore, the "acceptance criteria" presented are implicitly aligned with the performance and safety characteristics of the predicate device. The Ponto 4's reported performance is stated to be "as expected" and "as safe and effective" as the Ponto 3.

Table 1: Acceptance Criteria and Reported Device Performance

Performance MetricAcceptance Criteria (Implied by Predicate equivalency)Reported Device Performance (Ponto 4)
Electroacoustic Performance (General)Expected performance similar to Ponto 3 sound processors."The Ponto 4 sound processors are as safe and efficient as the Ponto 3 sound processors. In all instances, the Ponto 4 sound processors functioned and the performance observed was as expected." Specific electroacoustic tests included Maximum output responses, Output for full-on gain at 50 dB SPL and 60 dB SPL, Equivalent input noise level, Total harmonic distortion, Frequency range, Battery voltage, Current Consumption, Battery lifetime, IRIL (input related interference level), and Processing delay.
Maximum Output Force & GainEquivalent to predicate Ponto 3 sound processors."The maximum force output and gain of the Ponto 4 sound processor are equivalent to those provided by the predicate Ponto 3 sound processors."
Electromagnetic Compatibility (EMC)Compliance with EMC emissions and immunity standards (i.e., not emit excessive EM energy, operate without degradation in EM disturbance, and ESD protection)."Ponto 4 sound processors have also been tested to (1) not emit excessive amounts of electromagnetic energy (EMC emissions); (2) operate as intended without performance degradation in the presence of an electromagnetic disturbance (EMC immunity) and ESD."
BiocompatibilityMaterial safety and biocompatibility for human use."The Ponto 4 housing and coupling are made of medical grade plastics that have been shown to be biocompatible and safe for human use."
Functionality (Wireless connectivity)2.4 GHz Bluetooth wireless connectivity."The Velox S platform introduces wireless 2.4 GHz Bluetooth connectivity..."
Safety (Battery drawer, coupling)Tamper-proof battery drawer and maximum coupling safety release force, similar to Ponto 3."Tamper proof battery drawer Maximum coupling safety release force." (Listed in comparison table as identical to Ponto 3)

Study Information

The document describes the testing performed to demonstrate substantial equivalence, rather than a standalone clinical study to establish new performance metrics.

  1. Sample size used for the test set and the data provenance:

    • The document does not specify a sample size for a "test set" in terms of patient data.
    • The testing described is primarily for device-centric performance verification (electroacoustic and EMC), not clinical data from patients.
    • Data provenance: Not applicable in the context of patient data for a test set, as the testing focuses on the device itself. The studies are described as internal verification tests by the manufacturer, Oticon Medical AB (Sweden).
  2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

    • Not applicable as the testing is device-centric, not based on expert-adjudicated clinical data to establish a ground truth for a diagnostic or screening algorithm. The "truth" for electroacoustic measurements comes from established physical principles and measurement standards.
  3. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

    • Not applicable for the type of device-centric testing described.
  4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

    • No, an MRMC comparative effectiveness study was not conducted. This device is a hearing aid, not an AI-powered diagnostic or screening tool that would involve human "readers" or AI assistance in interpretation.
  5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

    • This is not an AI algorithm in the context of medical image analysis or diagnosis. The "standalone" performance refers to the device's inherent electroacoustic, EMC, and functional capabilities, which were indeed tested as described. The performance is assessed based on the device's output and specifications, without continuous human intervention during its operation.
  6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

    • For the device's performance testing (electroacoustic, EMC), the "ground truth" is based on engineering specifications, physical laws, and established measurement standards. For example, a nominal frequency response or maximum output level would be the "ground truth" against which the device's measured performance is compared.
    • For biocompatibility, the ground truth refers to established standards for medical-grade materials and their safety.
  7. The sample size for the training set:

    • Not applicable. This is not a machine learning or AI algorithm in the sense of requiring a training set from clinical data. The "training" for such devices involves product development, engineering design, and iterative testing.
  8. How the ground truth for the training set was established:

    • Not applicable, as there is no training set in the context of machine learning. The design and performance targets for the device are established through engineering design principles, previous device generations (Ponto 3), and relevant industry standards for hearing aids.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

May 6, 2019

Oticon Medical AB Lise Terkelsen Regulatory Affairs Manager Datavagen 37 B Askim, SE-436 32 Se

Re: K190540

Trade/Device Name: Ponto 4 Regulation Number: 21 CFR 874.3300 Regulation Name: Hearing Aid, Bone Conduction, Implanted Regulatory Class: Class II Product Code: LXB, MAH Dated: February 28, 2019 Received: March 4, 2019

Dear Lise Terkelsen:

This letter corrects our substantially equivalent letter of May 2, 2019.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

{1}------------------------------------------------

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Shu-Chen Peng

for Michael Ryan Director DHT1C: Division of ENT, Sleep Disordered Breathing, Respiratory and Anesthesia Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K190540

Device Name Ponto 4

Indications for Use (Describe)

Ponto 4 sound processors are intended for the following patients and indications:

· Patient with conductive or mixed hearing losses, who can still benefit from amplification of the sound. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear should be better than or equal to 45 dB HL for use with the Ponto 4 sound processor.

· Bilateral fitting is applicable for most patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2 and 4 kHz, or less than 15 dB at individual frequencies.

· Patients who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. single sided deafness or "SSD"). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz).

· Also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

The placement of a bone anchored implant is contraindicated for patient below the age of 5.

The Ponto 4 sound processors are intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS) (refer to the Ponto 4 labeling for specific compatible Cochlear models). In addition, selected Cochlear Baha sound processors can be used with the Ponto implant abutment system (refer to the Ponto labeling for compatible Baha sound processor models).

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW. The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) SUMMARY

Ponto 4

Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared

Submitter name:Oticon Medical AB
Address:Datavägen 37 BSE-436 32 AskimSweden
Phone:+46 31 748 61 00
Facsimile:+46 31 687 756
Contact Person:Lise Terkelsen
Mobile phone:+45 24 22 51 46
Date Prepared:May 1, 2019

Name of Device and Name/Address of Manufacturer

Ponto 4

Oticon Medical AB Datavägen 37 B SE-436 32 Askim Sweden

Common or Usual Name: Ponto bone anchored hearing system

Classification Name: Hearing aid, bone conduction

Classification Regulation: 21 C.F.R. §874.3300 (Product codes LXB, MAH)

Predicate Devices

Device510(k) no.Manufacturer
Predicate device: Ponto 3K161671Oticon Medical AB
Reference device: Oticon Opn S™ airconduction hearing aid with Bluetoothwireless connectivityExempt from 510kOticon A/S

{4}------------------------------------------------

Device Description

A bone anchored hearing system consists of a sound processor connected to an implant with a skin penetrating abutment. The implant is surgically anchored in the skull bone behind the ear. Vibrations generated by the sound processor are transmitted via the implant directly through the skull bone to the cochlea as bone conduction sound processor has a coupling so that it can be easily connected to and disconnected from the abutment by the user. Alternatively, it can be connected to head band accessories, to function as a conventional bone conductor. Using a computer based fitting system the sound processor can be adjusted to the patient's individual hearing requirements. The Ponto family is intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS).

Intended Use / Indications for Use

Intended use

The Ponto 4 sound processors are intended for improvement of hearing for patients with conductive and mixed hearing losses, bilateral fitting and single sided deafness.

Indications for use

Ponto 4 sound processors are intended for the following patients and indications:

· Patient with conductive or mixed hearing losses, who can still benefit from amplification of the sound. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear should be better than or equal to 45 dB HL for use with the Ponto 4 sound processor.

· Bilateral fitting is applicable for most patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2 and 4 kHz, or less than 15 dB at individual frequencies.

• Patients who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. single sided deafness or "SSD"). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz).

• Also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

The placement of a bone anchored implant is contraindicated for patient below the age of 5.

The Ponto 4 sound processors are intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS) (refer to the Ponto 4 labeling for specific compatible Cochlear models). In addition, selected Cochlear Baha sound processors can be used with the Ponto implant/abutment system (refer to the Ponto labeling for compatible Baha sound processor models).

{5}------------------------------------------------

Technological Characteristics

The Ponto 4 is a modification of the previously cleared sound processors (the Ponto 3, Power and Ponto 3 SuperPower in K161671), more specifically the Ponto 3 model, and represents the latest sound processor model in the Ponto bone anchored hearing system.

The Ponto 4 sound processor incorporates Velox S platform that is also used in the reference Oticon Opn S™ air conduction hearing aid legally marketed as class II, 510(k)-exempt devices. The Velox S platform introduces wireless 2.4 GHz Bluetooth connectivity and minor changes to the sound processing features. compared to the predicate Ponto 4 is smaller in size, which is enabled by moving the user controls to wireless accessories from Oticon A/S, and by smaller transducer and battery. Ponto 4 has a tamper resistant exchangeable battery drawer, side-neutral design, and a LED indicating status (e.g. low battery) of the sound processor.

The Ponto 4 housing and coupling are made of medical grade plastics that have been shown to be biocompatible and safe for human use.

This submission also includes minor modifications to the previously cleared accessory Genie Medical fitting software, and addition of compatibility with wireless accessories from Oticon A/S.

Discussion of testing

Testing of the Ponto 4 sound processors includes electroacoustic and EMC performance testing and firmware validation.

The Ponto 4 hardware is similar to Ponto 3 hardware, though smaller in size enabled by a smaller transducer and battery. The sound processing platform has been updated and a series of tests were conducted on the Ponto 4 sound processors to verify the design criteria and device performance with respect to electro acoustical performance. These tests include: Maximum output responses. Output for full-on gain at 50 dB SPL and 60 dB SPL, Equivalent input noise level, Total harmonic distortion, Frequency range, Battery voltage, Current Consumption, Battery lifetime, IRIL (input related interference level) and Processing delay, i.e. electro acoustical testing.

Ponto 4 sound processors have also been tested to (1) not emit excessive amounts of electromagnetic energy (EMC emissions); (2) operate as intended without performance degradation in the presence of an electromagnetic disturbance (EMC immunity) and ESD.

The above-mentioned tests verify that the Ponto 4 sound processors are as safe and efficient as the Ponto 3 sound processors. In all instances, the Ponto 4 sound processors functioned and the performance observed was as expected. Hence, we have come to the conclusion that further testing will not raise new issues of safety and efficacy.

Substantial Equivalence

The Ponto 4 sound processors have the same intended use as the Ponto 3 sound processor in K161671.

Ponto 4 sound processors have the similar principles of operations as the Ponto 3 sound processors. The sound processor is connected via an abutment to an implant placed in the temporal bone behind the ear, and the vibrations from the sound processor are transmitted directly to the inner ear through bone conduction. The implant and abutment are installed by a surgical procedure, and the sound processor can be connected and disconnected by the user by the snap coupling.

{6}------------------------------------------------

The sound processor is individually adjusted to the patient audiogram and needs by the Genie Medical fitting software by the audiologist. The volume and listening program can be changed by the user. On the predicate Ponto 3 sound processors this is done either on the sound processor itself or via the wireless accessories, whereas on the Ponto 4 the user can change the volume and program by using wireless accessories only. The same wireless remote functions are available for the predicate Oticon A/S 's Oticon S™ air conduction hearing aids, legally marketed as class II, 510(K)-exempt devices.

The sound processing platform and the wireless technology in the Ponto 4 sound processors are the same as those used in the legally marketed, class II 510(k)-exempt Oticon A/S air conduction hearing aids. The maximum force output and gain of the Ponto 4 sound processor are equivalent to those provided by the predicate Ponto 3 sound processors.

{7}------------------------------------------------

Comparison table

Ponto 4Ponto 3(K161671)Oticon Opn S™ airconduction hearing aidwith wirelesstechnology(legally marketed, class II510(k)-exempt)
Intended UseImprovement of hearing for patientswith conductive and mixed hearinglosses, whether unilaterally orbilaterally fitted or for those with singlesided deafness.SameTo amplify and transmitsound to the ear and herebycompensate for impairedhearing. Indicated for hearinglosses within mild-to- severe-to-profound range.
Indications forUse• Patient with conductive or mixedhearing losses, who can still benefitfrom amplification of the sound. Thepure tone average (PTA) boneconduction (BC) threshold (measuredat 0.5, 1, 2 and 3 kHz) of the indicatedear should be better than or equal to45 dB HL for use with the Ponto 4sound processor.• Bilateral fitting is applicable for mostpatients having a symmetricallyconductive or mixed hearing loss. Thedifference between the left and rightsides' BC thresholds should be lessthan 10 dB on average measured at0.5, 1, 2 and 4 kHz, or less than 15 dBat individual frequencies.• Patients who have a profoundsensorineural hearing loss in one earand normal hearing in the oppositeear (i.e. single sided deafness or"SSD"). The pure tone average (PTA)air conduction (AC) threshold of thehearing ear should then be better thanor equal to 20 dB HL (measured at0.5, 1, 2 and 3 kHz).• Also indicated for any patient who isindicated for an air-conductioncontralateral routing of signals (ACCROS) hearing aid, but who for somereason cannot or will not use an ACCROS.The placement of a bone anchoredimplant is contraindicated for patientbelow the age of 5.The Ponto 4 sound processors areintended to be used with either thePonto implant system or with specificcompatible BAHA abutments/implantsfrom Cochlear Bone AnchoredSolutions (BAS) (refer to the Ponto 4labeling for specific compatibleCochlear models). In addition,selected Cochlear Baha soundSameN/A
Soundprocessingfeaturesprocessors can be used with thePonto implant/abutment system (referto the Ponto 4 labeling for compatibleBaha sound processor models).
Open Sound Navigator Clear Dynamics Transient Noise Management Feedback Shield (LX) 64 Processing channels Speech Guard LX Wind noise management Battery management system Fitting bandwidth of 10 kHzFree Focus Multiband adaptive directionality Tri-state noise reduction Inium Sense feedback shield 15 sound processing channels Speech Guard Wind noise reduction Binaural processing Battery management systemSame (+ additional)
Fitting features16 channel frequency response shaping BC In-situ Audiometry Feedback Analyser OpenSound - Transition OpenSound - Noise reduction controls Wireless connection during fitting Data Logging Technical Measurement tool Verification tool FLogram Wireless accessories setting tool Visual indicators setting10 channel frequency response shaping BC In-situ Audiometry Feedback Manager Data Logging Technical Measurement tool Verification tool Streamer Settings tool (wireless accessory) Fitting Assistant tool FLogram16 channel frequency response shaping In-situ Audiometry Feedback Analyser OpenSound - Transition OpenSound - Noise reduction controls Wireless connection during fitting Wireless accessories setting tool Visual indicators setting
Wirelessreceiver /transducerReceiver and transmitter, 2.4 GHz, BluetoothReceiver and transmitter, 3.84 Mhz, Oticon proprietary NearLinkTwo wireless technologies with the commercial name TwinLink:Receiver and transmitter, 2.4 GHz, BluetoothReceiver and transmitter, 3.84 MHz, Oticon proprietary NearLink
CouplingMaterial: PEEK Snap coupling outside the abutmentSameN/A
AccessoriesOticon Medical accessories: Head band, test band, soft band and SoundConnector Genie Medical BAHS fitting software, version 2019.1 Skins for personalization Compatible wireless Oticon A/S accessories: Oticon ON App Remote control 3.0 ConnectClip TV Adapter 3.0 EduMicHead band, test band, soft band and SoundConnector Genie Medical fitting software, version 2016.1 Skins for personalization Compatible wireless Oticon A/S accessories: Connectline App Oticon Medical Streamer Compatible wireless Oticon A/S accessories through the Oticon Medical Streamer: Connectline TV Adapter Connectline microphone Connectline phone adapterGenie 2 fitting software Oticon ON App Remote control 3.0 ConnectClip TV Adapter 3.0 EduMic
SafetyFeaturesTamper proof battery drawer Maximum coupling safety release forceTamper proof battery drawer Maximum coupling safety release forceN/A

{8}------------------------------------------------

{9}------------------------------------------------

Conclusion

The minor technological differences between the Ponto 4 sound processors and their predicate devices raise no new issues of safety or effectiveness. Performance data demonstrate that the Ponto 4 sound processors are as safe and effective as the Ponto 3 sound processors. Thus, the Ponto 4 sound processors are substantially equivalent.

§ 874.3302 Bone-conduction hearing aid.

(a)
Identification. A bone-conduction hearing aid is a wearable sound-amplifying device intended to compensate for impaired hearing and that conducts sound to the inner ear through the skull. The non-implantable components of a bone-conduction hearing aid, such as the external sound processor, are subject to the requirements in § 801.422 of this chapter.(b)
Classification. Class II.